{"id":544261,"date":"2021-05-21T19:32:02","date_gmt":"2021-05-21T19:32:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=544261"},"modified":"2021-05-21T19:32:02","modified_gmt":"2021-05-21T19:32:02","slug":"parkinsons-disease-pd-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/parkinsons-disease-pd-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_544261.html","title":{"rendered":"Parkinson\u2019s Disease (PD) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"
\"Parkinson’s<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cParkinson\u2019s Disease (PD) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Parkinson\u2019s Disease (PD), historical and forecasted epidemiology as well as the Parkinson\u2019s Disease (PD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight has launched a new report on “Parkinson’s Disease (PD) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong>”.<\/p>\n

DelveInsight’s “Parkinson’s Disease (PD) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>” report delivers an in-depth understanding of the Parkinson’s Disease (PD), historical and forecasted epidemiology as well as the  Parkinson’s Disease (PD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    The total diagnosed prevalent population of Parkinson’s disease in the 7MM is expected to rise to 3,284,084 in 2030, during the study period [2017–2030]. Estimates show the highest diagnosed prevalent population of Parkinson’s disease is in the United States followed by Japan<\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1. Parkinson’s Disease (PD) market report covers a descriptive overview and comprehensive insight of the Parkinson’s Disease (PD) epidemiology and Parkinson’s Disease (PD) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2. The Parkinson’s Disease (PD) market report provides insights on the current and emerging therapies.<\/p>\n

    3. Parkinson’s Disease (PD) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4. The Parkinson’s Disease (PD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Parkinson’s Disease (PD) market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/parkinsons-disease-market-size-analysis-treatment<\/span><\/a>
    <\/a><\/strong><\/p>\n

    Parkinson’s Disease (PD): Overview<\/strong><\/p>\n

    Parkinson’s disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. Most people with Parkinson’s start to develop symptoms when they’re over 50, although around one in 20 people with the condition first experience symptoms when they’re under 40.<\/p>\n

    The key players involved in the Parkinson’s Disease (PD) market<\/a>:<\/strong><\/p>\n

      \n
    1. \n

      Neurocrine Biosciences\/Voyager Therapeutics<\/p>\n<\/li>\n

    2. \n

      Kyowa Kirin<\/p>\n<\/li>\n

    3. \n

      Neurocrine Biosciences<\/p>\n<\/li>\n

    4. \n

      Pharma Two B Ltd<\/p>\n<\/li>\n

    5. \n

      Luye Pharma<\/p>\n<\/li>\n

    6. \n

      AbbVie<\/p>\n<\/li>\n

    7. \n

      Sunovion Pharma<\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the Parkinson’s Disease (PD) treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        VY-AADC<\/p>\n<\/li>\n

      2. \n

        Istradefylline<\/p>\n<\/li>\n

      3. \n

        Opicapone<\/p>\n<\/li>\n

      4. \n

        P2B001<\/p>\n<\/li>\n

      5. \n

        LY03003<\/p>\n<\/li>\n

      6. \n

        ABBV-951<\/p>\n<\/li>\n

      7. \n

        APL-130277<\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/parkinsons-disease-market-size-analysis-treatment<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Parkinson’s Disease (PD) Patient Share (%) Overview at a Glance<\/p>\n

        5. Parkinson’s Disease (PD) Market Overview at a Glance<\/p>\n

        6. Parkinson’s Disease (PD) Disease Background and Overview<\/p>\n

        7. Parkinson’s Disease (PD) Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Parkinson’s Disease (PD)<\/p>\n

        9. Parkinson’s Disease (PD) Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Parkinson’s Disease (PD) Emerging Therapies<\/p>\n

        12. Parkinson’s Disease (PD) Market Outlook<\/p>\n

        13. Country-Wise Parkinson’s Disease (PD) Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Parkinson’s Disease (PD) Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Parkinson’s Disease- Pipeline Insights, 2021<\/strong><\/p>\n

        “Parkinson’s Disease Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Parkinson’s Disease market. A detailed picture of the Parkinson’s Disease pipeline landscape is provided, which includes the disease overview and Parkinson’s Disease treatment guidelines.<\/p>\n

        Parkinson’s Disease -Epidemiology Forecast to 2030<\/strong><\/p>\n

        DelveInsight’s ‘Parkinson’s Disease – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Parkinson’s Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cParkinson\u2019s Disease (PD) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Parkinson\u2019s Disease (PD), historical and forecasted epidemiology as well as the Parkinson\u2019s Disease (PD) market trends in the … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-544261","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=544261"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544261\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=544261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=544261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=544261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}